Ovarian cancer is the most frequent cause of  gynaecologic cancer-related mortality in  women. The overall 5-year survival of ovarian carcinoma is less  than 30%, creating a  pressing  need to understand its biology and  develop  effective and less toxic therapies for ovarian cancer. Ovaria  cancer is associated  with  a poor prognosis largely due to the advanced stage of disease at the  time of diagnosis.These  advanced stage  tumors  typically have  peritoneal  metastases  along with ascites fluid  accumulation  rendering them  principally  inoperable  and  unresponsive  to current treatment  options. Ovarian  carcinomas metastasize  by  attaching to  and  invading  through  the mesothelial lining of the peritoneal cavity. A practical and  effective screening  program for early detection of ovarian cancer would  therefore be a helpful mean.The techniques currently available-  transvaginal  ultrasound  and  CA125 (a biomarker of ovarian cancer) serum assays-are   problematic for  a  number of reasons. For example, CA125 is not consistently  elevated in  serum from patients with early-stage  disease and may be  elevated  in patients with   benign gynecologic  diseases.Details........       

             Lubna Yasmin